Global Upper-limb Robotic Neurorehabilitation Market

Upper-limb Robotic Neurorehabilitation Comprehensive Study by Type (Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems, Others), By End User (Hospitals & Clinics, Rehabilitation Centers, Research Institutions, Others), By Application (Stroke, Traumatic Brain Injury (TBI), Spinal Cord Injury (SCI), Parkinson's Disease, Brain Surgery, Others) Players and Region - Global Market Outlook to 2028

Upper-limb Robotic Neurorehabilitation Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Upper-limb Robotic Neurorehabilitation Market Scope
Upper-limb robotic neurorehabilitation is a type of therapy that uses robots to help people with upper-limb impairments improve their movement and function. Robots can provide repetitive, intensive, and task-specific training that can help to retrain the brain and muscles to move in a more coordinated and purposeful way. There are many different types of upper-limb robotic neurorehabilitation devices, but they all work in a similar way. The robot is attached to the person's arm and supports the arm as it moves through a series of exercises. The robot can provide resistance to movement, which can help to strengthen the muscles. It can also provide sensory feedback, which can help to improve the person's awareness of their arm position and movement.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBarrett (United Kingdom), Hocoma (Switzerland), Neuro Rehab VR (United States), BIONIK (United States), Medtronic (Ireland), Tyromotion GmbH (Austria), Ekso Bionics (United States), ReWalk Robotics (United States), BrainCo, Inc. (United States), Gloreha (United States), BTE Technologies, Inc. (United States), MediTouch Ltd. (Israel) and Ossur (Iceland)
CAGR%


The global Upper-limb robotic neurorehabilitation market is highly fragmented, with fierce competition among the top players for a large share of the global market. The majority of market players are vertically integrated, with a diverse product portfolio of Upper-limb robotic neurorehabilitation materials. Many players are arranging various strategies, entering into merger and acquisition to increased companies portfolio. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Upper-limb Robotic Neurorehabilitation market throughout the predicted period.

Barrett (United Kingdom), Hocoma (Switzerland), Neuro Rehab VR (United States), BIONIK (United States), Medtronic (Ireland), Tyromotion GmbH (Austria), Ekso Bionics (United States), ReWalk Robotics (United States), BrainCo, Inc. (United States), Gloreha (United States), BTE Technologies, Inc. (United States), MediTouch Ltd. (Israel) and Ossur (Iceland) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Upper-limb Robotic Neurorehabilitation market by Type and Region with country level break-up.

On the basis of geography, the market of Upper-limb Robotic Neurorehabilitation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
On November 2023, Reha Robotics and Ekso Bionics announced that they have merged to create a global leader in robotic exoskeleton technology for upper and lower extremity rehabilitation. The combined company will have a portfolio of FDA-cleared exoskeleton products.
On November 2023, Ekso Bionics announced the launch of its EksoNR robotic exoskeleton for neurorehabilitation. The EksoNR is designed to help individuals with upper extremity paralysis regain function in their arms and hands.


Influencing Trend:
Increasing Demand of Tele-rehabilitation, this will allow Patients to Received Therapy from the Comfort of their Own Homes

Market Growth Drivers:
Rising Incidence of Stroke and Growing Awareness of the Benefits of Robotic Neurorehabilitation

Challenges:
The High Competition among Major Players and There is a Lack of High-Quality Evidence to Support the Effectiveness of Robotic Neurorehabilitation

Restraints:
Robotic Therapy Systems are Expensive, Both in Terms of the Initial Purchase Price and the Ongoing Costs of Maintenance and Support and The Lack of Trained Therapists

Opportunities:
Technological Advancements are Making Robotic Neurorehabilitation Devices More Affordable and Easier to Use

Key Target Audience
Raw Material Providers, Device Manufacturer, Supplier & Distributer, Government Bodies, Research Organization and Others

Report Objectives / Segmentation Covered

By Type
  • Exoskeletons
  • End-effector Devices
  • Robotic Arms
  • Electrical Stimulation Devices
  • VR Systems
  • Others
By By End User
  • Hospitals & Clinics
  • Rehabilitation Centers
  • Research Institutions
  • Others

By By Application
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Spinal Cord Injury (SCI)
  • Parkinson's Disease
  • Brain Surgery
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Stroke
      • 3.2.2. Growing Awareness of the Benefits of Robotic Neurorehabilitation
    • 3.3. Market Challenges
      • 3.3.1. The High Competition among Major Players
      • 3.3.2. There is a Lack of High-Quality Evidence to Support the Effectiveness of Robotic Neurorehabilitation
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand of Tele-rehabilitation, this will allow Patients to Received Therapy from the Comfort of their Own Homes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Upper-limb Robotic Neurorehabilitation, by Type, By End User, By Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Upper-limb Robotic Neurorehabilitation (Value)
      • 5.2.1. Global Upper-limb Robotic Neurorehabilitation by: Type (Value)
        • 5.2.1.1. Exoskeletons
        • 5.2.1.2. End-effector Devices
        • 5.2.1.3. Robotic Arms
        • 5.2.1.4. Electrical Stimulation Devices
        • 5.2.1.5. VR Systems
        • 5.2.1.6. Others
      • 5.2.2. Global Upper-limb Robotic Neurorehabilitation by: By End User (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Rehabilitation Centers
        • 5.2.2.3. Research Institutions
        • 5.2.2.4. Others
      • 5.2.3. Global Upper-limb Robotic Neurorehabilitation by: By Application (Value)
        • 5.2.3.1. Stroke
        • 5.2.3.2. Traumatic Brain Injury (TBI)
        • 5.2.3.3. Spinal Cord Injury (SCI)
        • 5.2.3.4. Parkinson's Disease
        • 5.2.3.5. Brain Surgery
        • 5.2.3.6. Others
      • 5.2.4. Global Upper-limb Robotic Neurorehabilitation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Upper-limb Robotic Neurorehabilitation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Barrett (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hocoma (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Neuro Rehab VR (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BIONIK (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medtronic (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Tyromotion GmbH (Austria)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ekso Bionics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ReWalk Robotics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BrainCo, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Gloreha (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BTE Technologies, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. MediTouch Ltd. (Israel)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Ossur (Iceland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Upper-limb Robotic Neurorehabilitation Sale, by Type, By End User, By Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Upper-limb Robotic Neurorehabilitation (Value)
      • 7.2.1. Global Upper-limb Robotic Neurorehabilitation by: Type (Value)
        • 7.2.1.1. Exoskeletons
        • 7.2.1.2. End-effector Devices
        • 7.2.1.3. Robotic Arms
        • 7.2.1.4. Electrical Stimulation Devices
        • 7.2.1.5. VR Systems
        • 7.2.1.6. Others
      • 7.2.2. Global Upper-limb Robotic Neurorehabilitation by: By End User (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Rehabilitation Centers
        • 7.2.2.3. Research Institutions
        • 7.2.2.4. Others
      • 7.2.3. Global Upper-limb Robotic Neurorehabilitation by: By Application (Value)
        • 7.2.3.1. Stroke
        • 7.2.3.2. Traumatic Brain Injury (TBI)
        • 7.2.3.3. Spinal Cord Injury (SCI)
        • 7.2.3.4. Parkinson's Disease
        • 7.2.3.5. Brain Surgery
        • 7.2.3.6. Others
      • 7.2.4. Global Upper-limb Robotic Neurorehabilitation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Upper-limb Robotic Neurorehabilitation: by Type(USD Million)
  • Table 2. Upper-limb Robotic Neurorehabilitation Exoskeletons , by Region USD Million (2017-2022)
  • Table 3. Upper-limb Robotic Neurorehabilitation End-effector Devices , by Region USD Million (2017-2022)
  • Table 4. Upper-limb Robotic Neurorehabilitation Robotic Arms , by Region USD Million (2017-2022)
  • Table 5. Upper-limb Robotic Neurorehabilitation Electrical Stimulation Devices , by Region USD Million (2017-2022)
  • Table 6. Upper-limb Robotic Neurorehabilitation VR Systems , by Region USD Million (2017-2022)
  • Table 7. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2017-2022)
  • Table 8. Upper-limb Robotic Neurorehabilitation: by By End User(USD Million)
  • Table 9. Upper-limb Robotic Neurorehabilitation Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 10. Upper-limb Robotic Neurorehabilitation Rehabilitation Centers , by Region USD Million (2017-2022)
  • Table 11. Upper-limb Robotic Neurorehabilitation Research Institutions , by Region USD Million (2017-2022)
  • Table 12. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2017-2022)
  • Table 13. Upper-limb Robotic Neurorehabilitation: by By Application(USD Million)
  • Table 14. Upper-limb Robotic Neurorehabilitation Stroke , by Region USD Million (2017-2022)
  • Table 15. Upper-limb Robotic Neurorehabilitation Traumatic Brain Injury (TBI) , by Region USD Million (2017-2022)
  • Table 16. Upper-limb Robotic Neurorehabilitation Spinal Cord Injury (SCI) , by Region USD Million (2017-2022)
  • Table 17. Upper-limb Robotic Neurorehabilitation Parkinson's Disease , by Region USD Million (2017-2022)
  • Table 18. Upper-limb Robotic Neurorehabilitation Brain Surgery , by Region USD Million (2017-2022)
  • Table 19. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2017-2022)
  • Table 20. South America Upper-limb Robotic Neurorehabilitation, by Country USD Million (2017-2022)
  • Table 21. South America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 22. South America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 23. South America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 24. Brazil Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 25. Brazil Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 26. Brazil Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 27. Argentina Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 28. Argentina Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 29. Argentina Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 30. Rest of South America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 32. Rest of South America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 33. Asia Pacific Upper-limb Robotic Neurorehabilitation, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 36. Asia Pacific Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 37. China Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 38. China Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 39. China Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 40. Japan Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 41. Japan Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 42. Japan Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 43. India Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 44. India Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 45. India Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 46. South Korea Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 47. South Korea Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 48. South Korea Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 49. Taiwan Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 50. Taiwan Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 51. Taiwan Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 52. Australia Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 53. Australia Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 54. Australia Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 58. Europe Upper-limb Robotic Neurorehabilitation, by Country USD Million (2017-2022)
  • Table 59. Europe Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 60. Europe Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 61. Europe Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 62. Germany Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 63. Germany Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 64. Germany Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 65. France Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 66. France Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 67. France Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 68. Italy Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 69. Italy Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 70. Italy Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 71. United Kingdom Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 72. United Kingdom Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 73. United Kingdom Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 74. Netherlands Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 75. Netherlands Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 76. Netherlands Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 77. Rest of Europe Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 78. Rest of Europe Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 79. Rest of Europe Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 80. MEA Upper-limb Robotic Neurorehabilitation, by Country USD Million (2017-2022)
  • Table 81. MEA Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 82. MEA Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 83. MEA Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 84. Middle East Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 85. Middle East Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 86. Middle East Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 87. Africa Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 88. Africa Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 89. Africa Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 90. North America Upper-limb Robotic Neurorehabilitation, by Country USD Million (2017-2022)
  • Table 91. North America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 92. North America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 93. North America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 94. United States Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 95. United States Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 96. United States Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 97. Canada Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 98. Canada Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 99. Canada Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 100. Mexico Upper-limb Robotic Neurorehabilitation, by Type USD Million (2017-2022)
  • Table 101. Mexico Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2017-2022)
  • Table 102. Mexico Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2017-2022)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Upper-limb Robotic Neurorehabilitation: by Type(USD Million)
  • Table 117. Upper-limb Robotic Neurorehabilitation Exoskeletons , by Region USD Million (2023-2028)
  • Table 118. Upper-limb Robotic Neurorehabilitation End-effector Devices , by Region USD Million (2023-2028)
  • Table 119. Upper-limb Robotic Neurorehabilitation Robotic Arms , by Region USD Million (2023-2028)
  • Table 120. Upper-limb Robotic Neurorehabilitation Electrical Stimulation Devices , by Region USD Million (2023-2028)
  • Table 121. Upper-limb Robotic Neurorehabilitation VR Systems , by Region USD Million (2023-2028)
  • Table 122. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2023-2028)
  • Table 123. Upper-limb Robotic Neurorehabilitation: by By End User(USD Million)
  • Table 124. Upper-limb Robotic Neurorehabilitation Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 125. Upper-limb Robotic Neurorehabilitation Rehabilitation Centers , by Region USD Million (2023-2028)
  • Table 126. Upper-limb Robotic Neurorehabilitation Research Institutions , by Region USD Million (2023-2028)
  • Table 127. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2023-2028)
  • Table 128. Upper-limb Robotic Neurorehabilitation: by By Application(USD Million)
  • Table 129. Upper-limb Robotic Neurorehabilitation Stroke , by Region USD Million (2023-2028)
  • Table 130. Upper-limb Robotic Neurorehabilitation Traumatic Brain Injury (TBI) , by Region USD Million (2023-2028)
  • Table 131. Upper-limb Robotic Neurorehabilitation Spinal Cord Injury (SCI) , by Region USD Million (2023-2028)
  • Table 132. Upper-limb Robotic Neurorehabilitation Parkinson's Disease , by Region USD Million (2023-2028)
  • Table 133. Upper-limb Robotic Neurorehabilitation Brain Surgery , by Region USD Million (2023-2028)
  • Table 134. Upper-limb Robotic Neurorehabilitation Others , by Region USD Million (2023-2028)
  • Table 135. South America Upper-limb Robotic Neurorehabilitation, by Country USD Million (2023-2028)
  • Table 136. South America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 137. South America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 138. South America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 139. Brazil Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 140. Brazil Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 141. Brazil Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 142. Argentina Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 143. Argentina Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 144. Argentina Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 145. Rest of South America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 146. Rest of South America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 147. Rest of South America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 148. Asia Pacific Upper-limb Robotic Neurorehabilitation, by Country USD Million (2023-2028)
  • Table 149. Asia Pacific Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 150. Asia Pacific Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 151. Asia Pacific Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 152. China Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 153. China Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 154. China Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 155. Japan Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 156. Japan Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 157. Japan Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 158. India Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 159. India Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 160. India Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 161. South Korea Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 162. South Korea Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 163. South Korea Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 164. Taiwan Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 165. Taiwan Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 166. Taiwan Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 167. Australia Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 168. Australia Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 169. Australia Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 170. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 171. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 172. Rest of Asia-Pacific Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 173. Europe Upper-limb Robotic Neurorehabilitation, by Country USD Million (2023-2028)
  • Table 174. Europe Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 175. Europe Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 176. Europe Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 177. Germany Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 178. Germany Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 179. Germany Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 180. France Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 181. France Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 182. France Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 183. Italy Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 184. Italy Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 185. Italy Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 186. United Kingdom Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 187. United Kingdom Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 188. United Kingdom Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 189. Netherlands Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 190. Netherlands Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 191. Netherlands Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 192. Rest of Europe Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 193. Rest of Europe Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 194. Rest of Europe Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 195. MEA Upper-limb Robotic Neurorehabilitation, by Country USD Million (2023-2028)
  • Table 196. MEA Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 197. MEA Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 198. MEA Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 199. Middle East Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 200. Middle East Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 201. Middle East Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 202. Africa Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 203. Africa Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 204. Africa Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 205. North America Upper-limb Robotic Neurorehabilitation, by Country USD Million (2023-2028)
  • Table 206. North America Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 207. North America Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 208. North America Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 209. United States Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 210. United States Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 211. United States Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 212. Canada Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 213. Canada Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 214. Canada Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 215. Mexico Upper-limb Robotic Neurorehabilitation, by Type USD Million (2023-2028)
  • Table 216. Mexico Upper-limb Robotic Neurorehabilitation, by By End User USD Million (2023-2028)
  • Table 217. Mexico Upper-limb Robotic Neurorehabilitation, by By Application USD Million (2023-2028)
  • Table 218. Research Programs/Design for This Report
  • Table 219. Key Data Information from Secondary Sources
  • Table 220. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Upper-limb Robotic Neurorehabilitation: by Type USD Million (2017-2022)
  • Figure 5. Global Upper-limb Robotic Neurorehabilitation: by By End User USD Million (2017-2022)
  • Figure 6. Global Upper-limb Robotic Neurorehabilitation: by By Application USD Million (2017-2022)
  • Figure 7. South America Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 8. Asia Pacific Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 9. Europe Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 10. MEA Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 11. North America Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 12. Global Upper-limb Robotic Neurorehabilitation share by Players 2022 (%)
  • Figure 13. Global Upper-limb Robotic Neurorehabilitation share by Players (Top 3) 2022(%)
  • Figure 14. Global Upper-limb Robotic Neurorehabilitation share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Barrett (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Barrett (United Kingdom) Revenue: by Geography 2022
  • Figure 18. Hocoma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Hocoma (Switzerland) Revenue: by Geography 2022
  • Figure 20. Neuro Rehab VR (United States) Revenue, Net Income and Gross profit
  • Figure 21. Neuro Rehab VR (United States) Revenue: by Geography 2022
  • Figure 22. BIONIK (United States) Revenue, Net Income and Gross profit
  • Figure 23. BIONIK (United States) Revenue: by Geography 2022
  • Figure 24. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Medtronic (Ireland) Revenue: by Geography 2022
  • Figure 26. Tyromotion GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 27. Tyromotion GmbH (Austria) Revenue: by Geography 2022
  • Figure 28. Ekso Bionics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Ekso Bionics (United States) Revenue: by Geography 2022
  • Figure 30. ReWalk Robotics (United States) Revenue, Net Income and Gross profit
  • Figure 31. ReWalk Robotics (United States) Revenue: by Geography 2022
  • Figure 32. BrainCo, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. BrainCo, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Gloreha (United States) Revenue, Net Income and Gross profit
  • Figure 35. Gloreha (United States) Revenue: by Geography 2022
  • Figure 36. BTE Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. BTE Technologies, Inc. (United States) Revenue: by Geography 2022
  • Figure 38. MediTouch Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 39. MediTouch Ltd. (Israel) Revenue: by Geography 2022
  • Figure 40. Ossur (Iceland) Revenue, Net Income and Gross profit
  • Figure 41. Ossur (Iceland) Revenue: by Geography 2022
  • Figure 42. Global Upper-limb Robotic Neurorehabilitation: by Type USD Million (2023-2028)
  • Figure 43. Global Upper-limb Robotic Neurorehabilitation: by By End User USD Million (2023-2028)
  • Figure 44. Global Upper-limb Robotic Neurorehabilitation: by By Application USD Million (2023-2028)
  • Figure 45. South America Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 46. Asia Pacific Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 47. Europe Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 48. MEA Upper-limb Robotic Neurorehabilitation Share (%), by Country
  • Figure 49. North America Upper-limb Robotic Neurorehabilitation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Barrett (United Kingdom)
  • Hocoma (Switzerland)
  • Neuro Rehab VR (United States)
  • BIONIK (United States)
  • Medtronic (Ireland)
  • Tyromotion GmbH (Austria)
  • Ekso Bionics (United States)
  • ReWalk Robotics (United States)
  • BrainCo, Inc. (United States)
  • Gloreha (United States)
  • BTE Technologies, Inc. (United States)
  • MediTouch Ltd. (Israel)
  • Ossur (Iceland)
Select User Access Type

Key Highlights of Report


Dec 2023 228 Pages 89 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Upper-limb Robotic Neurorehabilitation Market Quantitative research analysis
Global Upper-limb Robotic Neurorehabilitation Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Upper-limb Robotic Neurorehabilitation Market are by type [Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems and Others], by end use application [].
The Upper-limb Robotic Neurorehabilitation Market is gaining popularity and expected to see strong valuation by 2028.
  • Rising Incidence of Stroke
  • Growing Awareness of the Benefits of Robotic Neurorehabilitation

Know More About Global Upper-limb Robotic Neurorehabilitation Market Report?

Have a Query? Click Here

Other Related Reports

TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis...
$ 3800
Hallux Rigidus Comprehensive Study by Treatment (-Non-Surgical Treatment, Shoe Modification, Orthotic Devices, Medications, Injection Therapy, Physical Therapy, -Surgical Treatment, Bone Spur Removal...
$ 3800
Teledermatology Comprehensive Study by Application (Direct consultations, Specialist referral, Online patient triage, Virtual prescription renewals, Patient follow-up care), Type (Synchronous, Asynch...
$ 3800
Retinal Detachment- Comprehensive Study by Type (Rhegmatogenous, Tractional, Exudative), Treatment Type (Surgical Others, Laser Therapy, Cryopexy, Others), End User (Hospitals, Speciality centre, Cl...
$ 3800
Autism Disorder and Treatment- Comprehensive Study by Therapy (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors (SSRI) /Antidepressants, Stimulants, Sleep Medications, Others), Type (Auti...
$ 3800
Bone Pain Treatment- Comprehensive Study by Treatment (Therapies, Surgery, Antibiotics, Others), Indication (Injury, Trauma, Bone Tumour, Infection, Others), End User (Hospital, Speciality Clinics, ...
$ 3800